A blood test detects Alzheimer's disease decades before symptoms emerge

Researchers have validated a blood test capable of detecting molecular hallmarks of Alzheimer's disease with 93% diagnostic accuracy—a significant step toward identifying the disease in asymptomatic stages. The method amplifies trace amounts of misfolded amyloid-β protein (Aβ) through repeated sonication cycles, following a prion-like mechanism where small corrupt aggregates seed the misfolding of native proteins. In a study of 549 participants recruited between December 2020 and May 2024, plasma Aβ aggregation activity showed strong correlations with cognitive decline: MMSE scores (rs = −0.68) and CDR scores (rs = 0.71). Optimized cutoff values (42.91 for distinguishing Alzheimer's from cognitively unimpaired; 42.02 for Alzheimer's versus other dementias) also enable differentiation of mild cognitive impairment due to Alzheimer's from other dementia forms. For the longevity-conscious reader, this biomarker offers an unprecedented intervention window: detecting brain pathology years or decades before cognitive symptoms appear, fundamentally shifting the secondary prevention paradigm for Alzheimer's disease.